Ropeginterferon alfa-2b + Ruxolitinib combination (myelofibrosis)

Current understanding

First-in-class combination adding ropeginterferon alfa-2b (long-acting pegylated interferon) on top of ongoing ruxolitinib (JAK1/2 inhibitor) in myelofibrosis, currently under early clinical trial evaluation (RopeRux in Myelofibrosis) for tolerability and efficacy. Rationale combines two distinct mechanisms — JAK inhibition for spleen/symptom control with interferon-driven disease modification and potential allele-burden reduction — in a setting where neither agent alone is curative. Evidence is trial-early; safety of the dual cytokine/JAKi exposure (cytopenias, immune-related events) is the primary near-term question.

Evidence log

Open questions

Related